Total for the last 12 months
number of access : ?
number of downloads : ?
ID 118952
Author
Shimamoto, Yusaku Osaka International Cancer Institute
Takeuchi, Yoji Osaka International Cancer Institute|Gunma University
Ishiguro, Shingo PCL Osaka Pathology and Cytology Center
Nakatsuka, Shin-ichi Osaka International Cancer Institute
Yunokizaki, Hiroshi Ishikawa Gastroenterology Clinic
Ezoe, Yasumasa Kyoto University
Nakajima, Takeshi Kyoto University
Tanaka, Kumiko Tokushima University
Ishihara, Ryu Osaka International Cancer Institute
Yoshida, Teruhiko National Cancer Center Hospital
Sugano, Kokichi Kyoundo Hospital
Mutoh, Michihiro Kyoto Prefectural University of Medicine
Ishikawa, Hideki Ishikawa Gastroenterology Clinic|Kyoto Prefectural University of Medicine
Keywords
adenomatous polyposis coli
desmoid tumor
duodenal neoplasm
familial adenomatous polyposis
gastric lesion
genotype-phenotype correlation
Content Type
Journal Article
Description
Familial adenomatous polyposis (FAP) patients develop various life-threatening extracolonic comorbidities that appear individually or within a family. This diversity can be explained by the localization of the adenomatous polyposis coli (APC) variant, but few reports provide definitive findings about genotype–phenotype correlations. Therefore, we investigated FAP patients and the association between the severe phenotypes and APC variants. Of 247 FAP patients, 126 patients from 85 families identified to have APC germline variant sites were extracted. These sites were divided into six groups (Regions A to F), and the frequency of severe comorbidities was compared among the patient phenotypes. Of the 126 patients, the proportions of patients with desmoid tumor stage ≥III, number of FGPs ≥1000, multiple gastric neoplasms, gastric neoplasm with high-grade dysplasia, and Spigelman stage ≥III were 3%, 16%, 21%, 12%, and 41%, respectively, while the corresponding rates were 30%, 50%, 70%, 50%, and 80% in patients with Region E (codons 1398–1580) variants. These latter rates were significantly higher than those for patients with variants in other regions. Moreover, the proportion of patients with all three indicators (desmoid tumor stage ≥III, number of FGPs ≥1000, and Spigelman stage ≥III) was 20% for those with variants in Region E and 0% for those with variants in other regions. Variants in Region E indicate aggressive phenotypes, and more intensive management is required.
Journal Title
Cancer Science
ISSN
13497006
Publisher
Japanese Cancer Association|John Wiley & Sons
Volume
114
Issue
12
Start Page
4596
End Page
4606
Published Date
2023-10-05
Rights
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
EDB ID
DOI (Published Version)
URL ( Publisher's Version )
FullText File
language
eng
TextVersion
Publisher
departments
University Hospital
Medical Sciences